Literature DB >> 20527735

Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes.

José Villalaín1.   

Abstract

Arbidol, a broad and potent antiviral molecule, incorporates rapidly into membranes. To gain further insight into the mode of action of Arbidol, since the exact antiviral mechanism of Arbidol is unknown, I examined its interaction and effects on model membranes composed of saturated phospholipids by performing a detailed biophysical study using calorimetry and infrared spectroscopy. Arbidol interacts and modifies the physicochemical properties of the phospholipids in the membrane, having a significant effect on negatively charged phospholipids but a minor one on zwitterionic phospholipids. The data suggest that Arbidol is located at the interface of the membrane, participates in hydrogen bonding either with water or the phospholipid or both, and decreases the hydrogen bonding network of the phospholipids giving place to a phospholipid phase similar to the dehydrated solid one. The significant effects produced on negatively charged phospholipids suggest that the active molecule of Arbidol in the membrane is the protonated one, that is, the positively charged molecule. These data suggest that the potent antiviral effects of Arbidol are mediated at least in part through its membranotropic effects, likely giving place to the formation of perturbed membrane structures. These modifications interfere with proper membrane functioning and should be responsible for its broad antiviral activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527735     DOI: 10.1021/jp102619w

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  23 in total

1.  Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin.

Authors:  Evelien Vanderlinden; Els Vanstreels; Eline Boons; Wouter ter Veer; Anke Huckriede; Dirk Daelemans; Alfons Van Lommel; Erzsébet Rőth; Ferenc Sztaricskai; Pàl Herczegh; Lieve Naesens
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

2.  5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses.

Authors:  Che C Colpitts; Alexey V Ustinov; Raquel F Epand; Richard M Epand; Vladimir A Korshun; Luis M Schang
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

3.  Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol.

Authors:  Elodie Teissier; Giorgia Zandomeneghi; Antoine Loquet; Dimitri Lavillette; Jean-Pierre Lavergne; Roland Montserret; François-Loïc Cosset; Anja Böckmann; Beat H Meier; François Penin; Eve-Isabelle Pécheur
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

Review 4.  Early Events in Chikungunya Virus Infection-From Virus Cell Binding to Membrane Fusion.

Authors:  Mareike K S van Duijl-Richter; Tabitha E Hoornweg; Izabela A Rodenhuis-Zybert; Jolanda M Smit
Journal:  Viruses       Date:  2015-07-07       Impact factor: 5.048

Review 5.  Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community.

Authors:  Zichao Luo; Melgious Jin Yan Ang; Siew Yin Chan; Zhigao Yi; Yi Yiing Goh; Shuangqian Yan; Jun Tao; Kai Liu; Xiaosong Li; Hongjie Zhang; Wei Huang; Xiaogang Liu
Journal:  Research (Wash D C)       Date:  2020-06-16

Review 6.  Emerging Pharmaceutical Treatments of Novel COVID-19: A Review.

Authors:  Azhar Hussain; Jasndeep Kaler; Arun Kumar Dubey
Journal:  Cureus       Date:  2020-05-24

7.  Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses.

Authors:  Jan Haviernik; Michal Štefánik; Martina Fojtíková; Sabrina Kali; Noël Tordo; Ivo Rudolf; Zdeněk Hubálek; Luděk Eyer; Daniel Ruzek
Journal:  Viruses       Date:  2018-04-10       Impact factor: 5.048

Review 8.  Potential treatment methods targeting 2019-nCoV infection.

Authors:  Lu Zheng; Lina Zhang; Jiamin Huang; Kutty Selva Nandakumar; Shuwen Liu; Kui Cheng
Journal:  Eur J Med Chem       Date:  2020-07-28       Impact factor: 6.514

Review 9.  Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.

Authors:  Ilad Alavi Darazam; Shervin Shokouhi; Masoud Mardani; Mohamad Amin Pourhoseingholi; Mohammad Mahdi Rabiei; Firouze Hatami; Minoosh Shabani; Omid Moradi; Farid Javandoust Gharehbagh; Seyed Sina Naghibi Irvani; Mahdi Amirdosara; Mohammadreza Hajiesmaeili; Omidvar Rezaei; Ali Khoshkar; Legha Lotfollahi; Latif Gachkar; Hadiseh Shabanpour Dehbsneh; Negar Khalili; Azam Soleymaninia; Akram Hoseyni Kusha; Maryam Taleb Shoushtari; Parham Torabinavid
Journal:  Int Immunopharmacol       Date:  2021-07-10       Impact factor: 4.932

10.  A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.

Authors:  Wenyu Chen; Ming Yao; Zhixian Fang; Xiaodong Lv; Min Deng; Zhen Wu
Journal:  J Med Virol       Date:  2020-06-19       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.